S L Silverman, E Siris, D L Kendler, D Belazi, J P Brown, D T Gold, E M Lewiecki, A Papaioannou, C Simonelli, I Ferreira, A Balasubramanian, P Dakin, P Ho, S Siddhanti, B Stolshek, C Recknor
UNLABELLED: To determine persistence with subcutaneous denosumab every 6 months in women being treated for osteoporosis, we conducted a single-arm prospective, observational study in the United States and Canada. Among 935 patients enrolled, 12-month persistence was 82%, with 66 patients (7%) reporting serious adverse events and 19 patients (2%) reporting fractures. INTRODUCTION: Increased persistence with osteoporosis therapy is associated with reduced fracture risk...
January 2015: Osteoporosis International